Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Current Deferred Revenue (2021 - 2025)

Historic Current Deferred Revenue for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to $526000.0.

  • ARS Pharmaceuticals' Current Deferred Revenue changed N/A to $526000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $526000.0, marking a year-over-year change of. This contributed to the annual value of $557000.0 for FY2024, which is N/A changed from last year.
  • ARS Pharmaceuticals' Current Deferred Revenue amounted to $526000.0 in Q3 2025.
  • In the past 5 years, ARS Pharmaceuticals' Current Deferred Revenue registered a high of $3.1 million during Q4 2022, and its lowest value of $10000.0 during Q1 2023.
  • Over the past 5 years, ARS Pharmaceuticals' median Current Deferred Revenue value was $557000.0 (recorded in 2024), while the average stood at $996142.9.
  • Within the past 5 years, the most significant YoY rise in ARS Pharmaceuticals' Current Deferred Revenue was 11530.54% (2022), while the steepest drop was 11530.54% (2022).
  • ARS Pharmaceuticals' Current Deferred Revenue (Quarter) stood at $1.5 million in 2021, then skyrocketed by 115.31% to $3.1 million in 2022, then plummeted by 99.68% to $10000.0 in 2023, then skyrocketed by 5470.0% to $557000.0 in 2024, then decreased by 5.57% to $526000.0 in 2025.
  • Its Current Deferred Revenue was $526000.0 in Q3 2025, compared to $746000.0 in Q2 2025 and $540000.0 in Q1 2025.